Clinical Trials Browser

Recruiting × INDUSTRY × pomalidomide × Clear all

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT05438043 2026-03-16

A Study of Daratumumab

Phase 3 Recruiting

Multiple Myeloma

NCT06158841 2026-03-13

CERVINO

Phase 3 Recruiting

Multiple Myeloma

NCT06208150 2026-03-13

MonumenTAL-6

Phase 3 Recruiting

Multiple Myeloma

NCT06768489 2026-03-13

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT05519085 2026-03-11

SUCCESSOR-1

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT06953960 2026-02-23

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Phase 1/2 Recruiting

Multiple Myeloma, Neoplasms

NCT04973605 2026-02-20

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06152575 2026-02-03

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05020236 2026-02-02

MAGNETISMM-5

Phase 3 Recruiting

Multiple Myeloma

NCT05137054 2026-01-22

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Phase 1 Recruiting

Multiple Myeloma

NCT07312188 2025-12-31

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT06464991 2025-07-20

FUMANBA-03

Phase 3 Recruiting

Multiple Myeloma

NCT05828459 2025-03-20

First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

Phase 1 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms